Alzheimer Disease as a Clinical-Biological Construct-An International Working Group Recommendation.

Authors

Bruno Dubois, Nicolas Villain, Lon Schneider, Nick Fox, Noll Campbell, Douglas Galasko, Miia Kivipelto, Frank Jessen, Bernard Hanseeuw, Mercè Boada, Frederik Barkhof, Agneta Nordberg, Lutz Froelich, Gunhild Waldemar, Kristian Steen Frederiksen, Alessandro Padovani, Vincent Planche, Christopher Rowe, Alexandre Bejanin, Agustin Ibanez, Stefano Cappa, Paulo Caramelli, Ricardo Nitrini, Ricardo Allegri, Andrea Slachevsky, Leonardo Cruz de Souza, Andrea Bozoki, Eric Widera, Kaj Blennow, Craig Ritchie, Marc Agronin, Francisco Lopera, Lisa Delano-Wood, Stéphanie Bombois, Richard Levy, Madhav Thambisetty, Jean Georges, David T Jones, Helen Lavretsky, Jonathan Schott, Jennifer Gatchel, Sandra Swantek, Paul Newhouse, Howard H Feldman, Giovanni B Frisoni

Abstract

Since 2018, a movement has emerged to define Alzheimer disease (AD) as a purely biological entity based on biomarker findings. The recent revision of the Alzheimer's Association (AA) criteria for AD furthers this direction. However, concerns about a purely biological definition of AD being applied clinically, the understanding of AD by society at large, and the translation of blood-based biomarkers into clinical practice prompt these International Working Group (IWG) updated recommendations.

PMID:39483064 | DOI:

UK DRI Authors

Prof Nick Fox

Group Leader

Accelerating the development of effective therapies to make a difference for people living with dementia

Prof Nick Fox

Prof Jonathan Schott

Group Leader

Clinical academic specialising in dementia, with a focus on early accurate diagnosis, detection of pre-symptomatic Alzheimer’s disease, and promoting healthy cognitive ageing.

Prof Jonathan Schott